Drug Update · Neurology

FDA Approves efgartigimod alfa for gMG: 67.7% MG‑ADL Response

July 16, 2026

FDA supplemental approval date

2026-05-08

Label effective date

2026-05-13

MG-ADL responder rate (Study 1, anti‑AChR positive)

67.7% vs 29.7% (efgartigimod vs placebo)

QMG responder rate (Study 1)

63.1% vs 14.1% (efgartigimod vs placebo)

Pivotal trial enrollment (ADAPT/Study 1)

167 patients (84 efgartigimod; 83 placebo)

Clinical Perspective

This approval affects neurologists, neuromuscular specialists, and advanced practice clinicians managing adults with generalized myasthenia gravis by adding a subcutaneous, patient/caregiver‑administerable formulation of efgartigimod alfa ^[2]. The source‑confirmed data support use of efgartigimod alfa for gMG based on randomized phase 3 evidence showing higher MG‑ADL and QMG responder rates versus placebo in antibody‑positive patients and a bridging study supporting SC pharmacodynamics comparable to IV administration ^[2]^[1]. Important unanswered questions include optimal patient selection and timing for repeat SC treatment cycles and how the SC regimen performs in broader real‑world seronegative subgroups over longer follow‑up?

Dr. Vikram Patel · Neurology

VYVGART HYTRULO (efgartigimod alfa-fcab coformulated with hyaluronidase) received a supplemental FDA approval for generalized myasthenia gravis (gMG) with label action effective 2026-05-13, based on randomized trials that established efficacy of efgartigimod alfa and a pharmacodynamic bridging study showing the subcutaneous formulation produced comparable pharmacodynamic effects to the intravenous formulation ^[2]. In Study 1 (EFG IV), efgartigimod alfa achieved a 67.7% MG‑ADL responder rate versus 29.7% with placebo in anti‑AChR antibody–positive patients ^[2]^[1].

Clinical Context

Efgartigimod alfa is a human IgG1 Fc fragment engineered to bind the neonatal Fc receptor (FcRn) and reduce circulating IgG; the approved subcutaneous coformulation (VYVGART HYTRULO) includes hyaluronidase to facilitate SC administration ^[2]. The FDA originally approved efgartigimod alfa intravenous in 2023 and the most recent supplemental approval and label revision for the subcutaneous formulation are recorded in May 2026 ^[2]. The efficacy base includes two randomized, double‑blind, placebo‑controlled phase 3 trials (one in anti‑AChR antibody–positive patients and one in antibody‑negative patients) for generalized myasthenia gravis and a bridging study showing comparable pharmacodynamic effects between IV and SC formulations ^[2]^[1]. The subcutaneous prefilled syringe may be administered by patients or caregivers after instruction; a vial formulation is intended for healthcare‑administered use ^[2].

Key Findings

The primary efficacy result supporting approval derived from Study 1 (EFG IV), in which efgartigimod alfa achieved an MG‑ADL responder rate of 67.7% versus 29.7% with placebo in the anti‑AChR antibody–positive population during the first treatment cycle (primary endpoint) ^[2].
In the same population, the QMG responder rate during the first treatment cycle was 63.1% for efgartigimod alfa versus 14.1% for placebo (secondary endpoint) ^[2].
The pivotal randomized trial (ADAPT / Study 1) enrolled 167 patients randomized 1:1 to efgartigimod alfa IV (n=84) or placebo (n=83); 129 (77%) were anti‑AChR antibody–positive, and the primary analysis population included the antibody‑positive modified intent‑to‑treat cohort ^[1]^[2].
The FDA label notes that efficacy of the subcutaneous coformulation (VYVGART HYTRULO) was established by two multicenter randomized placebo‑controlled trials (one each in anti‑AChR antibody positive and antibody negative patients) and a bridging pharmacodynamic study (Study 3) that demonstrated comparable pharmacodynamic effects of the SC formulation vs the IV formulation ^[2].

Safety & Tolerability

Headache was reported (efgartigimod 24 [29%] vs placebo 23 [28%]) in the ADAPT study ^[1].
Nasopharyngitis was reported (efgartigimod ten [12%] vs placebo 15 [18%]) in ADAPT ^[1].
Treatment‑emergent adverse events occurred in 65 (77%) of 84 efgartigimod‑treated patients and 70 (84%) of 83 placebo patients in ADAPT; serious adverse events occurred in four (5%) efgartigimod‑treated patients and seven (8%) placebo patients; three patients in each group (4%) discontinued treatment during the study; there were no deaths in the trial ^[1].
The FDA label for the subcutaneous formulation instructs clinicians to evaluate the need for age‑appropriate vaccines before initiating a new treatment cycle because VYVGART HYTRULO causes transient reduction in IgG levels; vaccination with live vaccines is not recommended during treatment cycles ^[2].

Study Design

The efficacy dossier included two multicenter, randomized, double‑blind, placebo‑controlled phase 3 trials for generalized myasthenia gravis (one in anti‑AChR antibody–positive patients and one in anti‑AChR antibody–negative patients) and a pharmacodynamic bridging study comparing SC and IV formulations ^[2]^[1]. ADAPT (Study 1) enrolled 167 patients (84 efgartigimod IV; 83 placebo) across 56 sites; the primary endpoint was proportion of anti‑AChR antibody–positive patients who were MG‑ADL responders (≥2‑point improvement sustained ≥4 weeks) during the first treatment cycle ^[1]^[2]. Approval of the subcutaneous coformulation was based on these data plus Study 3 demonstrating comparable pharmacodynamic effect to the IV formulation ^[2].

FAQ

Q1 What is VYVGART HYTRULO (efgartigimod alfa‑fcab) approved for?

VYVGART HYTRULO is approved for the treatment of adult patients with generalized myasthenia gravis (gMG). The FDA approval for the subcutaneous coformulation was supported by randomized phase 3 trials demonstrating efficacy of efgartigimod alfa in gMG and by a bridging study showing comparable pharmacodynamic effects of the subcutaneous formulation versus the intravenous formulation. Clinicians should consult current prescribing information for complete dosing guidance.

Q2 How does efgartigimod alfa (VYVGART HYTRULO) work?

Efgartigimod alfa is a human IgG1 antibody fragment that binds the neonatal Fc receptor (FcRn), resulting in reduction of circulating IgG levels. The subcutaneous product combines efgartigimod alfa with hyaluronidase, which transiently increases subcutaneous tissue permeability to facilitate SC administration; tissue permeability is restored within 24 to 48 hours. This mechanism aims to lower pathogenic IgG autoantibodies implicated in myasthenia gravis.

Q3 What is the recommended dose of VYVGART HYTRULO for gMG?

The approved dosing regimen for generalized myasthenia gravis is a cycle of once‑weekly subcutaneous injections for 4 weeks. For the prefilled syringe formulation the recommended dose is 1,000 mg efgartigimod alfa with 10,000 units hyaluronidase administered subcutaneously over approximately 20 to 30 seconds; the single‑dose vial contains 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase administered over approximately 30 to 90 seconds. Subsequent treatment cycles are administered based on clinical evaluation. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects of efgartigimod alfa?

In the pivotal randomized trial (ADAPT), the most frequently reported adverse events included headache (efgartigimod 24 [29%] vs placebo 23 [28%]) and nasopharyngitis (efgartigimod ten [12%] vs placebo 15 [18%]). Treatment‑emergent adverse events occurred in 65 (77%) of 84 efgartigimod‑treated patients and 70 (84%) of 83 placebo patients; serious adverse events were reported in four (5%) efgartigimod‑treated patients and seven (8%) placebo patients; three patients in each group discontinued treatment; there were no deaths in the study. The FDA label also recommends evaluating vaccination status before initiating a treatment cycle because treatment causes transient IgG reduction and live vaccines are not recommended during treatment cycles.

FDA Approves efgartigimod alfa for gMG: 67.7% MG‑ADL Response

Direct Clinical Takeaway & Evidence Summary

FDA Approves efgartigimod alfa for gMG: 67.7% MG‑ADL Response

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Neurology in your inbox.

Related Clinical Updates

FDA Approves Efgartigimod for gMG: 67.7% MG-ADL Response

Oveporexton: Increases Wakefulness (MWT) 25.4 min in Narcolepsy Type 1

FDA Approves Leucovorin for Cerebral Folate Transport Deficiency

Verified HCP Portal